Lung cancer updates from @JSabari of @nyulangone @Perlmutter_CC new data #ASCO26 @Aiims1742 @nyugrossman

From emerging therapies to new clinical research, #ASCO2026 brings oncology experts to Chicago, May 29–June 2. Join us for presentations from @nyulangone physicians and researchers. Check out the full list of our presenters: bit.ly/4fdKFt2

Join Natasha B. Leighl, MD, MMSc, FRCPC, FASCO, FCAHS, Pasi A. Jänne, MD, PhD, FASCO, and Joshua Sabari, MD (@JSabari), on 5/30 at 6:30 PM CDT during #ASCO26 for an #NSCLC #MedEd event. Produced with @LUNGevity ➡️ bit.ly/2026EGFRLung-T #Oncology

🚨@OncBrothers are moderating the 3rd Annual Upstate Cancer Symposium! ⭐️Full Day CME event bringing the latest in oncology to community practice! @PTarantinoMD @jainprantesh @rukitamehta @rutikamehtaMD @DrR_DUNNE #OncTwitter #MedTwitter Full details: oncupdates.com/article/oncol…

First line oral targeted therapy for advanced non small cell lung cancer, including responses observed in dreaded brain metastatic disease (thanks to the chemistry behind Zongertinib crossing BBB). New study in @NEJM nejm.org/doi/full/10.1056/NE… @JSabari @Perlmutter_CC

Permitting NGS results do not identify oncogenic drivers or co-mutations that would favor alternative approaches (i.e., non IO, TKI instead).

FDA approval for lung cancer med Hernexeos fiercepharma.com/pharma/boeh… @Perlmutter_CC @nyulangone @EGFRResisters @Exon20Group

Zongertinib (oral TKI) now @US_FDA approved based off #BeamionLung1 in previously treated metastatic NSCLC w/ HER2+: - 71% ORR w/ 14.1mos mDoR - mPFS 12.4% - ≥Gr 3 AEs in less than 20%. Common AEs includied diarrhea and rash #OncTwitter #MedTwitter

FDA approves zongertinib 120mg po daily for previously treated advanced #HER2 NSCLC. In the phase 1b Beamion-LUNG 1 study @NEJM, RR 71% (42% post ADC), DOR 14.1m, intracranial RR 41%. Main toxicity is diarrhea (56%, 48% grade 1), no ILD. fda.gov/drugs/resources-info…

Proud to work here @nyulangone @Perlmutter_CC

Honored to be an Expert Judge Mentor for #EGFRSummit! Submit your abstracts by 8/8 to be part of the next class of @EGFRSummit Young Investigators! ➡️ ce.ceconcepts.com/EGFR2025CF… #EGFR #LCSM #MedTwitter #MedEd

Discussing data hot off the press here at #HawaiiLung25. Dr. Joshua Sabari reviews the latest FDA approval of DatoDXd for our patients with EGFR+ mNSCLC.

Advancements Reshape Treatment for Non-Small Cell Lung Cancer @JSabari @Perlmutter_CC @jainprantesh @RoswellPark #LungCancer curetoday.com/view/advanceme…

📣 HCPs 📣 Do you treat pts w/ rare alterations of #NSCLC? Medical Oncologist Dr @JSabari and Debra Montague (President of @LungCancerEu/founder of @UKALK1) share views on: ➡️The pt pathway ➡️#MedOnc vs Patient needs ➡️The support currently available Watch the video/listen on Spotify/Apple: cor2ed.com/lung-connect/prog… 🤝Endorsed by several Patient Advocacy Groups, inc. @WarOnCancer @BrafBombers @Exon20Group @metcrusaders @BiomarkerCo @LungCancerEu & ALK Positive Europe Supported by an Independent Educational Grant from Boehringer Ingelheim #MedEd #NSCLC #PrecisionMedicine 📷

Join Joshua Sabari, MD (@JSabari), Jonathan W. Goldman, MD, Gilberto Lopes, MD, MBA, FASCO (@GlopesMd), Zosia Piotrowska, MD, MHS (@ZPiotrowskaMD) & @OncBrothers, on 5/31 at 6:30 PM CDT during #ASCO25 for an #NSCLC #MedEd event. Produced w/ @Lungevity. bit.ly/25TT-T

Getting excited for ASCO 2025! Join us Sat, May 31 at The Sheraton Grand Chicago Riverwalk in Chicago 6 Ballroom for #PrecisionMedicine in #NSCLC at #ASCO25! 6:30 PM CDT Reg & Dinner | 7 PM CDTSymposium. @PeerView @LUNGevity @OncBrothers ➡️ bit.ly/25TT-T

Real World Data on Overall Survival in EGFR mutant NSCLC treated with first line Osimertinib @Perlmutter_CC @nyulangone @JTOonline jto.org/article/S1556-0864(2…